Genus (FRA:GBE) Debt-to-Asset : 0.28 (As of Dec. 2023)

View and export this data going back to 2011. Start your Free Trial

What is Genus Debt-to-Asset?

Genus's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €21.5 Mil. Genus's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €317.6 Mil. Genus's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2023 was €1,223.3 Mil. Genus's debt to asset for the quarter that ended in Dec. 2023 was 0.28.

Genus Debt-to-Asset Historical Data

The historical data trend for Genus's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genus Debt-to-Asset Chart

Genus Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Debt-to-Asset

Get a 7-Day Free Trial

0.14

0.17

0.18

0.22

0.23

Genus Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Asset	Get a 7-Day Free Trial															0.21	0.22	0.25	0.23	0.28

Competitive Comparison of Genus's Debt-to-Asset

For the Biotechnology subindustry, Genus's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Genus's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genus's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Genus's Debt-to-Asset falls into.

Genus Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Genus's Debt-to-Asset for the fiscal year that ended in Jun. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(16.549	+	253.942)	/	1174.145
	=	0.23

Genus's Debt-to-Asset for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(21.474	+	317.584)	/	1223.324
	=	0.28

Genus (FRA:GBE) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Genus Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Genus's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Genus (FRA:GBE) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genus PLC (FRA:GBE) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

GENSF:USA GNSl:UK GNS:UK

Address

Matrix House, Basing View, Basingstoke, Hants, GBR, RG21 4DZ

Website

https://www.genusplc.com

Genus PLC is a biotechnology company that develops animal genetics for agricultural purposes. The company breeds and distributes the genes of pigs and bulls, scientifically selecting livestock whose offspring are designed to increase the profitability of its customers. In the porcine market, Genus sells boars and sows that produce offspring with desirable characteristics, such as feed-efficient growth or leaner meat. In the dairy and beef markets, the company's primary product is bull semen, which is delivered through artificial insemination to improve its customers' herds and their efficiency. Genus also offers embryos through its subsidiary IVB.

Genus (FRA:GBE) Headlines

No Headlines